

Special Issue

Herpesvirus-Specific Immunomonitoring in Patient Groups of Increased Risk

Message from the Guest Editors

Herpesviruses may cause severe, even life-threatening disease in high-risk individuals, such as intensive care patients, HIV-infected people with AIDS, cancer patients, and in solid organ or bone marrow transplants. Mostly, severe diseases occur when the host's immunity is compromised due to aging, co-infections, or another underlying disease. Understanding the risk factors associated with a more severe course of the disease will help to improve prophylactic and therapeutic interventions against these viruses. We highly encourage the submission of articles to this Special Issue, which will contribute to a better understanding of the risk factors that are associated with a higher frequency of reactivations or a more severe disease. Furthermore, we accept manuscripts describing the herpesvirus-specific immunomonitoring in patient groups of increased risk. Identification of novel vaccine candidates or therapeutics, which can protect from disease or suppress the virus replication is important, articles on this topic are also welcome.



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4

CiteScore 9.9

Indexed in PubMed



mdpi.com/si/66968

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](http://mdpi.com/journal/vaccines)

Guest Editors

Prof. Dr. Oliver Witzke

Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, D-45147 Essen, Germany

Dr. Adalbert Krawczyk

Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, D-45147 Essen, Germany

Deadline for manuscript submissions

closed (31 March 2022)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](http://mdpi.com/journal/vaccines)

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

